Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.
Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, Khamesipour A, Jalali T, Nakhaeizadeh M, Sharifi H, Mansoori Y, Keramat F, Ghodrati S, Javanian M, Doroud D, Omrani MD, Asadi H, Pouriayevali MH, Ghasemian R, Farshidi H, Pourahmad M, Ghasemzadeh I, Mounesan L, Darvishian M, Mirjalili MR, Toledo-Romani ME, Valenzuela-Silva C, Verez-Bencomo V, Gouya MM, Emadi-Koochak H, Haghdoost AA, Biglari A; Soberana Study Group.
Mostafavi E, et al.
JAMA Netw Open. 2023 May 1;6(5):e2310302. doi: 10.1001/jamanetworkopen.2023.10302.
JAMA Netw Open. 2023.
PMID: 37133864
Free PMC article.
Clinical Trial.
The study was conducted from April 26 to September 25, 2021. INTERVENTIONS: In cohort 1, 2 doses of FINLAY-FR-2 (n = 13 857) or placebo (n = 3462) were administered 28 days apart. In cohort 2, 2 doses of FINLAY-FR-2 plus 1 dose of FINLAY-FR-1A (n = 4340) or 3 …
The study was conducted from April 26 to September 25, 2021. INTERVENTIONS: In cohort 1, 2 doses of FINLAY-FR-2 (n = 13 857) or place …